Falsey RR, et al
The clinical presentation can vary widely depending on the type of mutation affecting SLC22A5 and the phenotypic manifestation of the mutation, i.e., age of onset, organ involvement, and severity of symptoms at the time of diagnosis (34)
Phosphorolysis of glycogen provides higher levels of glucose-6-phosphate (G6P), an important intermediate in the glycolysis pathway ( FIGURE 1 From an energetic point of view, glycolysis is not efficient
Adams, T.E
Key Features Research Use Only (RUO) compound 5 mg per vial lyophilized powder format for convenient handling in laboratory settings Manufactured and packaged for research applications Product Specifications Compound Name: AOD-9604 Form: Lyophilized Powder Total Quantity: 5 mg per Vial Grade: Research Use Only (RUO) Intended Use This product is intended solely for laboratory research and investigational purposes
The Peptide Clarity Handbook: A Beginners Guide to Safe Peptide Therapy, BPC-157, TB-500, and Science-Based Peptide Protocols for Healing, Recovery, and